Prelude Capital Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-504,972
| Closed | -$7.55M | – | 1689 |
|
|
2022
Q4 | $7.55M | Buy |
+504,972
| New | +$6.99M | 0.39% | 36 |
|
|
2019
Q1 | – | Sell |
-14
| Closed | – | – | 2365 |
|
|
2018
Q4 | $0 | Sell |
14
-7
| -33% | -$154 | ﹤0.01% | 2343 |
|
|
2018
Q3 | $1K | Buy |
21
+13
| +163% | +$334 | ﹤0.01% | 1693 |
|
|
2018
Q2 | $0 | Sell |
8
-13,142
| -100% | -$312K | ﹤0.01% | 2079 |
|
|
2018
Q1 | $381K | Hold |
13,150
| – | – | 0.03% | 509 |
|
|
2017
Q4 | $367K | Buy |
13,150
+4,379
| +50% | +$136K | 0.03% | 497 |
|
|
2017
Q3 | $320K | Buy |
8,771
+8,381
| +2,149% | +$259K | 0.03% | 501 |
|
|
2017
Q2 | $9K | Buy |
+390
| New | +$3.07K | ﹤0.01% | 1417 |
|
|
2016
Q4 | – | Sell |
-100
| Closed | -$1K | – | 1899 |
|
|
2016
Q3 | $1K | Sell |
100
-60
| -38% | -$565 | ﹤0.01% | 1552 |
|
|
2016
Q2 | $2K | Buy |
+160
| New | +$1.54K | ﹤0.01% | 1522 |
|
|
2014
Q2 | – | Sell |
-120
| Closed | -$2K | – | 2277 |
|
|
2014
Q1 | $2K | Buy |
+120
| New | +$2.15K | ﹤0.01% | 1817 |
|
Prelude Capital Management's AVEO Position: Q1 2023 in Review
Prelude Capital Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2023, closing a stake of 504,972 shares — an estimated $7.55M sold.
Prelude Capital Management first reported a position in AVEO in Q1 2014 and held it in 11 quarters. The position peaked at $7.55M in Q4 2022. 0 funds tracked by Wall St. Rank hold AVEO as of Q1 2023.
- Prelude Capital Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Prelude Capital Management sold 504,972 AVEO Pharmaceuticals, Inc. shares in Q1 2023, an estimated $7.55M.
- Prelude Capital Management first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2014 and held it in 11 quarters.
- Prelude Capital Management's AVEO Pharmaceuticals, Inc. position peaked at $7.55M in Q4 2022.
- 0 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2023.
Based on Prelude Capital Management's 13F filing for Q1 2023, filed 15 May 2023.